Latest news with #TUS
&w=3840&q=100)
Business Standard
3 days ago
- General
- Business Standard
Indian youth spend more time on work, women continue to get a raw deal
In 2019, out of the 1,440 minutes in a day, Indian youth spent 148 minutes on employment-related activities, which increased to 158 minutes in 2024 Amitava Saha Gopal Saha Listen to This Article Time Use Survey (TUS) plays a pivotal role in understanding how individuals across different age groups and gender participate in paid and unpaid activities. TUS data depicts how gender norms and societal roles influence the way men and women divide their time, both within the household and in broader society. Recognising the importance of unpaid work by women, the United Nations, in its 2030 agenda for Sustainable Development, has introduced an indicator for measuring the 'proportion of time spent on unpaid domestic and care work, by sex, age, and location,' to track progress towards gender equality and women empowerment.
Agriland
5 days ago
- Business
- Agriland
DkIT students represent Ireland at AgriNext competition
Seven students from the third year of the bachelor of science in Sustainable Agriculture programme at Dundalk Institute of Technology (DkIT) represented Ireland at the AgriNext 'Dream Job = Green Job' video trailer competition which took place in Cordoba, Spain recently. Lauren Acheson, Katie Cooney, Chantelle Ging, Keva Keogh, Millie Rice, Caoimhe Tully, and Rachel White made up the two teams from Ireland, demonstrating DkIT's advocacy for multifunctional agriculture. The students took part in an intensive week of intercultural events, educational workshops, and farm visits with other students from Spain, Croatia, Slovenia and Hungary. The entry from Biotehniski Center Naklo in Slovenia was announced as the winner for their video titled: 'How buying food locally supports multifunctional agriculture'. Speaking on return from the trip, Eamon Mullen, lecturer at the Department of Agriculture, Food and Animal Health at DkIT said: 'This was an amazing experience for our students and they represented themselves, DkIT and Ireland admirably. 'The event was a fantastic way to showcase the efforts that the participants from all across Europe are making to use multifunctional agriculture as a means to make farming a viable, environmentally responsible and socially beneficial activities for farmers and their communities. 'We'd like to especially thank Elaine Cleary and all the team at TUS (Technological University of the Shannon) for the opportunity to enter this competition and for making the experience so memorable and rewarding.' The event was organised as part of the Erasmus+ Agri-Next project which is a partnership between several educational and rural development institutions from across Europe. Leading in Ireland is the Sustainable Development Research Institute (SDRI) based in Thurles, which is part of the Technological University of the Shannon (TUS). Speaking about the programme, Elaine Cleary, researcher at the SDRI said: 'It is a fantastic project to showcase how flexible learning can enhance multi-functional opportunities in farming across Europe and we are delighted to be working on the next steps, including a Business Incubator Centre to create a learning environment where educators, industry experts and employers can interact.' Cordoba is located in the Andalusia region of southern Spain and has the unique distinction of being the only city in the world with four UNESCO World Heritage sites. Most of the events were based at the Galileo Galilei Centre of Excellence in the Vocational Training campus, which offers courses in sectors ranging from agriculture and emergency services to sociocultural studies and community care. During the stay, the DkIT students were treated to an authentic Andalusian welcome and experienced the rich heritage of the region, with everything from Spanish tapas dining, kayaking along the Guadalquivir River, exploring the prehistoric caves of Cueva de los Murcielagos, watching classical and Andalusian horse-riding, to listening to the unique flamenco style of music and dancing. The promotion of multifunctional agriculture was the central theme of the campus events held throughout the week. This approach encourages farmers to combine traditional farming with non-traditional activities – such as agritourism, renewable energy production, or educational programmes – to generate financial, environmental, and social benefits for both themselves and their communities. As part of the Agri-Next competition, DkIT teams created videos showcasing how farmers could diversify their operations to embrace this model. These ideas were further explored in a series of workshops, where participants shared best practices, exchanged ideas, and learned from one another's experiences. DkIT students DkIT student Caoimhe Tully described the week as 'an incredible opportunity', noting 'it was great to meet students from across Europe and learn about different approaches to sustainable farming'. 'The workshops and farm visits gave us a real insight into how multifunctional agriculture can work in practice,' she added. One of the highlights of the trip was a visit to an agro-livestock farm based in the hills outside the city. The farm encompassed the whole farm-to-fork concept by rearing its own livestock and then having the meat from the herd available in its restaurant which is also situated on the farm. The week finished with a visit to the college's own farm (La Finca) to view the horticultural, livestock, and equestrian facilities, and officially ended with a traditional Andalusian tapas lunch prepared by the headmaster of the college and its staff. Reflecting on the experience, DkIT student Katie Cooney said: 'It was such a great opportunity to learn about how different countries are creating innovative ways to improve farm diversification, and to also meet lots of different people from agricultural backgrounds.' Head of Department of Agriculture, Food and Animal Health at DkIT, Dr. Siobhán Jordan said: 'We are incredibly grateful for this valuable opportunity and enriching experience for our students. 'Sincere thanks to Elaine Cleary from the Sustainable Development Research Institute at TUS and the AgriNext Project for organising this initiative. It provided our students with a unique chance to explore agricultural diversification and innovation on an international stage.'
Ottawa Citizen
14-05-2025
- Business
- Ottawa Citizen
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Article content Article content SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. Article content The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. Article content Details of the presentation are as follows: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Session: Oral Presentations: Acute Myeloid Leukemia – Clinical Session Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CEST Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Article content Article content The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. Article content The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available.
Yahoo
14-05-2025
- Business
- Yahoo
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and 80 mg dose levels and longer duration SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. Details of the presentation are as follows:Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction ChemotherapySession: Oral Presentations: Acute Myeloid Leukemia – ClinicalSession Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CESTPresenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of MedicineAbstract #: S139 Abstracts are available on the EHA2025 website here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Dublin Live
07-05-2025
- Business
- Dublin Live
Social welfare Ireland: Thousands have rates slashed in 2025 for one reason
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info Some 3,000 people have had their social welfare rates cut in 2025 for not engaging with unemployment services. This compares to just 10,200 people in the entirety of 2024. The data was released to People Before Profit TD Paul Murphy following a parliamentary question to Social Protection Minister Dara Calleary. The Fianna Fáil Minister argued that 'entitlement to a jobseeker payment is dependent on the recipient being available for, capable of and genuinely seeking work'. Mr Calleary continued: 'This reflects the concept of 'rights and responsibilities' whereby people who are unemployed have the right to an income support from the State and a right to be supported in their efforts to secure employment, but also have a responsibility to seek employment and to engage with the employment services offered by the State. 'Intreo Employment Services supports jobseekers to find work and there are a wide range of supports on offer in terms of further education, training, upskilling, work placements, as well as programmes such as Community Employment and TUS.' He further explained that people who do not engage with Intreo could see their benefits reduced and they can be 'subsequently disqualified from their payment for up to nine weeks'. The amount of money a person's benefit can be docked by each week increased from €44 to €90 in January. Mr Calleary confirmed to Deputy Murphy that in the first three months of 2025 alone, 3,008 people saw their rates reduced. There were 10,232 people impacted in the entirety of 2024 and another 5,235 penalised in 2023. There were 888 people penalised in March, 1,360 in February and 760 in January. The number of people who had their money cut in February 2025 was up 169 per cent compared to February 2024, when 505 people were cut. Minister Calleary continued: "Reduced rates were introduced as a means of encouraging jobseekers to engage proactively with Intreo Employment Services to assist them find a pathway to employment. A reduced rate is a final step in a process to encourage a jobseeker to avail of employment supports on offer and once a jobseeker resumes this engagement, the reduced rate is lifted immediately. 'Whether a reduced rate applies and the duration of its application is totally within the control of the claimant.' Deputy Murphy said that he was concerned about the 'sharp increase in the number of people having their supports cut'. He said: 'We're talking about people here who are trying to pay their bills, many trying to raise a family, while also facing the stress of being temporarily unemployed. They can't afford these cuts. "My office has also noticed an increased number of people contacting us because they've felt pressured into taking up so-called 'internships' and various 'schemes' which are not relevant or helpful for their careers. I am very worried that a Thatcherite agenda is being pursued here, squeezing people's incomes and pushing into JobBridge 2.0 type scams." Join our Dublin Live breaking news service on WhatsApp. Click this link to receive your daily dose of Dublin Live content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice. For all the latest news from Dublin and surrounding areas visit our homepage.
